Company: KROS
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001664710-25-000018
Chunk: 176

Company: Keros Therapeutics, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 8
Chunk 176
---
Net loss per share attributable to common stockholders—basic and diluted$(5.00)$(5.20)$(4.15)Weighted-average common stock outstanding—basic and diluted37,437,652 29,447,119 25,241,030 

See notes to consolidated financial statements.

F-5

KEROS THERAPEUTICS, INC.

 Consolidated Statements of Stockholders’ Equity 

(In thousands, except share and per share data)

COMMON STOCK$0.0001 PAR VALUEADDITIONALPAID-INCAPITALACCUMULATEDDEFICITTOTAL STOCKHOLDERS’  EQUITYSHARESAMOUNTBALANCE, January 1, 202223,974,834 $2 $366,927 $(123,755)$243,174 Issuance of common stock under the ATM agreement, net of commissions and offering cost of $1,9713,410,384 — 119,428 — 119,428 Exercise of common stock options158,235 — 818 — 818 Stock-based compensation— — 18,682 — 18,682 Net loss— — — (104,679)(104,679)BALANCE, December 31, 202227,543,453 $2 $505,855 $(228,434)$277,423 Issuance of common stock under the ATM agreement, net of commissions and offering cost of $2,7084,061,606 1 175,793 — 175,794 Exercise of common stock options236,025 — 3,225 — 3,225 Stock-based compensation— — 28,763 — 28,763 Net loss— — — (152,992)(152,992)BALANCE, December 31, 202331,841,084 $3 $713,636 $(381,426)$332,213 Issuance of common stock, net of underwriting discounts, commissions and offering costs of $9,9434,025,000 — 151,057 — 151,057 Issuance of common stock under the ATM agreement, net of commissions and offering cost of $3,655 4,290,096 1 228,622 — 228,623 Exercise of common stock options398,525 — 12,141